✨ Free AI Report
AVROBIO, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research AVROBIO, Inc.
Company Research

AVROBIO, Inc.: Business Overview, Financials & Competitive Analysis

AVROBIO, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Rare disease gene therapy platform with meaningful clinical-stage assets now backed by GPCR-focused parent company Tectonic Therapeutic. AVROBIO possesses innovative first-in-class gene therapy candidates for rare monogenic diseases with strong scientific backing, but faces typical biotech execution risks. The June 2024 acquisition by Tectonic Therapeutic signals confidence in the platform.

What is AVROBIO, Inc.'s industry? AVROBIO, Inc. (avrobio.com) operates in Gene Therapy. AskCyborg classifies AVROBIO, Inc. under Gene Therapy in its company registry.

AVROBIO develops gene therapies by introducing functional copies of affected genes into patients' own hematopoietic stem cells (HSCs), with the goal of durably expressing therapeutic proteins throughout the body, incl...

5/ 10Mixed

Cyborg Score thesis

Rare disease gene therapy platform with meaningful clinical-stage assets now backed by GPCR-focused parent company Tectonic...

Read the full analyst-debate transcript →
Industry Gene Therapy
3 named competitors
1 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest AVROBIO, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for AVROBIO, Inc.

AskCyborg analysts argue the bull and bear cases for AVROBIO, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
AVROBIO, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

AVROBIO, Inc. Overview

Pro stress-test →

AVROBIO develops gene therapies by introducing functional copies of affected genes into patients' own hematopoietic stem cells (HSCs), with the goal of durably expressing therapeutic proteins throughout the body, including the central nervous system. The company's pipeline includes clinical programs for Gaucher disease and Hunter syndrome, as well as a preclinical program for Pompe disease.

Strategic Profile

Pro stress-test →

AVROBIO's proprietary plato® gene therapy platform is scalable for planned global commercialization. The company was acquired by Tectonic Therapeutic on June 20, 2024, positioning it within a combined entity focused on next-generation therapeutic approaches for rare genetic diseases.

Competitive Landscape

Pro stress-test →

Competitors in the rare genetic disease and gene therapy space include Orchard Therapeutics, Ultragenyx Pharmaceutical, NexImmune, and Arno Therapeutics. Direct competitors for lysosomal storage disorder therapies include companies developing AAV and lentiviral gene therapy platforms.

Industry Context

AVROBIO, Inc. operates in Gene Therapy.

Key facts

Founded: 2015 · Headquarters: Cambridge, MA · Employees: 22 · Revenue: $25.8M

What the analysts stress-tested

The top findings that survived the multi-agent debate for AVROBIO, Inc..

  • Uses ex-vivo gene therapy approach targeting hematopoietic stem cells for genetic disease treatment
  • Acquired by Tectonic Therapeutic in June 2024, combining with a GPCR-therapeutic protein developer
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • June 2024Acquired by Tectonic Therapeutic in all-stock merger transaction
Get alerted when AVROBIO, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Orchard TherapeuticsGene therapy for rare genetic diseases→Ultragenyx PharmaceuticalRare genetic disease therapeutics→NexImmuneCell therapy platform for immune disorders→

Compare AVROBIO, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

AVROBIO, Inc. operates in Gene Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Gene Therapy research →
NEW · MCP server

Ask your AI assistant about AVROBIO, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare AVROBIO, Inc. and its top competitor on Cyborg Score”
“What did AVROBIO, Inc. do this quarter?”
“Is AVROBIO, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does AVROBIO, Inc. do?+
AVROBIO develops gene therapies by introducing functional copies of affected genes into patients' own hematopoietic stem cells (HSCs), with the goal of durably expressing therapeutic proteins throughout the body, incl...
What is AVROBIO, Inc.'s Cyborg Score?+
AVROBIO, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are AVROBIO, Inc.'s main competitors?+
Named competitors include Orchard Therapeutics, Ultragenyx Pharmaceutical, NexImmune. The full competitive landscape is in the AskCyborg report.
How can I get the full AVROBIO, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the AVROBIO, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track AVROBIO, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Gene Therapy research

Companies in the same sector and named competitors, ranked by Cyborg Score.

4uniQure N.V.